Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment 
Apple Faces Margin Pressure as Memory Chip Prices Surge Amid AI Boom 
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Boeing Secures New Labor Contract With Former Spirit AeroSystems Employees 
Jensen Huang Urges Taiwan Suppliers to Boost AI Chip Production Amid Surging Demand 
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI 
Oracle Plans $45–$50 Billion Funding Push in 2026 to Expand Cloud and AI Infrastructure 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
American Airlines Plans Return to Venezuela Flights After U.S. Lifts Ban 
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Apple Forecasts Strong Revenue Growth as iPhone Demand Surges in China and India 
WALTHAM, Mass., May 30, 2017 -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat central nervous system (CNS) disorders, today announced that it will present at the Jefferies 2017 Global Healthcare Conference on June 6, 2017 at 11:00 a.m. Eastern Time.
The presentation will be webcast and accessible through the investor relations section of the Company’s web site, http://ir.minervaneurosciences.com.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of product candidates to treat CNS diseases. Minerva’s proprietary compounds include: MIN-101, in clinical development for schizophrenia; MIN-117, in clinical development for major depressive disorder (MDD); MIN-202 (JNJ-42847922), in clinical development for insomnia and MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.” For more information, please visit www.minervaneurosciences.com.
Contact: William B. Boni VP, Investor Relations/ Corp. Communications Minerva Neurosciences, Inc. (617) 600-7376
